<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hand, Larry</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Kosiborod, Mikhail</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Ranolazine Provides Benefit over Placebo for T2DM Patients with Angina</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">21-22</style></pages><abstract><style  face="normal" font="default" size="100%">In a trial focused on the treatment of stable angina in patients with type 2 diabetes, ranolazine significantly reduced the frequency of angina episodes compared with placebo. This article presents the results of the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina study [TERISA; Kosiborod M et al. J Am Coll Cardiol 2013].</style></abstract><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>